statistiche ricercatore

DE LERMA BARBARO, ANDREA

Distribuzione geografica

Continente	#
NA - Nord America	5.992
EU - Europa	5.096
AS - Asia	2.673
SA - Sud America	265
AF - Africa	32
OC - Oceania	11
Continente sconosciuto - Info sul continente non disponibili	5
Totale	14.074

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	5.816
IT - Italia	2.508
SG - Singapore	993
UA - Ucraina	957
CN - Cina	436
TR - Turchia	384
VN - Vietnam	383
SE - Svezia	376
HK - Hong Kong	340
DE - Germania	273
FI - Finlandia	268
BR - Brasile	232
IE - Irlanda	205
GB - Regno Unito	154
RU - Federazione Russa	129
CA - Canada	127
FR - Francia	119
IN - India	52
MX - Messico	41
PL - Polonia	25
JP - Giappone	22
ZA - Sudafrica	18
ES - Italia	16
BD - Bangladesh	15
AR - Argentina	13
NL - Olanda	13
BE - Belgio	12
IQ - Iraq	12
AT - Austria	9
NZ - Nuova Zelanda	9
CH - Svizzera	8
LT - Lituania	8
CZ - Repubblica Ceca	7
CO - Colombia	6
PK - Pakistan	6
UZ - Uzbekistan	6
AE - Emirati Arabi Uniti	5
EG - Egitto	5
EU - Europa	5
PY - Paraguay	5
SA - Arabia Saudita	5
RS - Serbia	4
KE - Kenya	3
KR - Corea	3
LB - Libano	3
MA - Marocco	3
AU - Australia	2
DK - Danimarca	2
DZ - Algeria	2
EC - Ecuador	2
GR - Grecia	2
PE - Perù	2
TT - Trinidad e Tobago	2
UY - Uruguay	2
AZ - Azerbaigian	1
BB - Barbados	1
BH - Bahrain	1
BY - Bielorussia	1
CL - Cile	1
CR - Costa Rica	1
GL - Groenlandia	1
GY - Guiana	1
HN - Honduras	1
ID - Indonesia	1
JM - Giamaica	1
KH - Cambogia	1
MO - Macao, regione amministrativa speciale della Cina	1
PA - Panama	1
PH - Filippine	1
PS - Palestinian Territory	1
TN - Tunisia	1
TW - Taiwan	1
VE - Venezuela	1
Totale	14.074

Salva come PNG Salva come JPEG

Città	#
Milan	1.837
Jacksonville	724
Singapore	576
Chandler	529
Ashburn	453
Fairfield	453
Woodbridge	354
Hong Kong	339
Wilmington	259
Princeton	245
Ann Arbor	229
Izmir	229
Nyköping	216
Dallas	215
Beijing	210
Dublin	205
Dearborn	194
Seattle	194
Houston	180
Dong Ket	155
Boardman	147
Cambridge	134
Rome	126
Como	103
Toronto	99
San Mateo	92
New York	89
The Dalles	88
Los Angeles	68
San Diego	55
Chicago	48
Ogden	38
Munich	34
Düsseldorf	29
Santa Clara	29
São Paulo	28
London	26
Mexico City	23
Verona	23
Warsaw	23
Pune	22
Hefei	20
Orem	20
Tokyo	20
Guangzhou	19
Helsinki	18
Chennai	17
Ho Chi Minh City	17
Council Bluffs	16
Manchester	16
Turku	16
Nanjing	15
Brooklyn	13
Brussels	12
Johannesburg	12
Kunming	11
Hanoi	10
Stockholm	10
Boston	9
Frankfurt am Main	9
Montreal	9
Norwalk	9
Phoenix	9
St Petersburg	9
Denver	8
Jinan	8
Poplar	8
Redwood City	8
Atlanta	7
Christchurch	7
Fuzhou	7
Ponte Lambro	7
Raleigh	7
San Francisco	7
Shanghai	7
Washington	7
Auburn Hills	6
Curitiba	6
Querétaro	6
Rozzano	6
Villanova D'asti	6
Zhengzhou	6
Amsterdam	5
Changsha	5
Charlotte	5
Falls Church	5
Goiânia	5
Vanzaghello	5
Baghdad	4
Belgrade	4
Cape Town	4
Casorezzo	4
Columbus	4
Hebei	4
Hounslow	4
Nuremberg	4
Ottawa	4
Ribeirão Preto	4
San Jose	4
Seveso	4
Totale	9.638

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy	208
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	204
Surface protein components from entomopathogenic nematodes and their symbiotic bacteria: effects on immune responses of the greater wax moth, Galleria mellonella (Lepidoptera: Pyralidae)	193
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	186
The MHC class II transactivator: prey and hunter in infectious diseases	183
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	182
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human	181
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.	175
New strategies of mammary cancer vaccination	171
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	168
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	164
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review)	162
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.	156
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	151
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	151
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	149
In Vivo Effects of A Pro-PO System Inhibitor on the Phagocytosis of Xenorhabdus Nematophila in Galleria Mellonella Larvae	149
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	148
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	144
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2	142
Analysis of microchimerism in thyroid autoimmune diseases	141
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	141
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy	140
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	139
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	135
Antitumor vaccines and immunotherapeutic strategies based on CIITA-driven MHC class II espression in cancer cells.	132
Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and partecipatine in the development of anti-inflammatory functional behavior of phagocytic macrophages	130
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	130
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	130
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	130
The complex liaison between cachexia and tumor burden	130
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	128
Therapy-induced antitumor vaccination by targeting tumor necrosis factor  to tumor vessels in combination with melphalan	128
CIITA-driven MHC-II+ tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy.	127
MHC immunoevasins: protecting the pathogen reservoir in infection	126
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	124
CIITA reduced transcription as the cause of HLA class II downregulation in human macrophages during bacterial phagocytosis	123
CIITA-driven MHC class II expressing tumor cells of distinct hystotype act as a potent antitumor vaccine and as a superior generators of tumor-specific CD4+ T lymphocytes for immunotherapy.	123
Physiologic target of the Air-1 trans-activator revealed by stable transfection assay	123
Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules	122
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA	122
Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells	122
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	121
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	121
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions	120
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	120
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	119
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	119
Therapy-induced antitumor vaccination by targeting TNFa to tumor vessels in combination with melphalan	116
Regulation of HLA antigen expression in HIV infected cells	116
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	115
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA	114
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules	114
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	114
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	114
Tumor rejection and anti-tumor memory to cancer cells of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. A new strategy of anti-tumor vaccination and tumor immunotherapy.	112
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication	112
The utility of introducing a measurement of tumor burden for a better assessment of cancer cachexia.	110
Characterization of an epigenetic variant lacking MHC-II inducibility by IFN-g in the promyelocytic cell line THP-1	108
Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan	108
Espressione delle molecole HLA di classe II in cellule di epatocarcinoma classe II negative dopo trasfezione del transattivatore CIITA. Acquisizione della capacità di processare e presentare l'antigene	107
The AIR-1 locus encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 replication by blocking the function of HIV-1 Tat	107
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	106
Regolazione dell'espressione dei geni del Complesso Maggiore di Istocompatibilità HLA e di CD4 in cellule infettate da HIV: effetto di TAT	106
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down-modulation in normal human macrophages during bacterial phagocytosis	105
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity.	105
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	105
Inibizione della replicazione virale di HIV-1 e HTLV-2 da parte di CIITA il regolatore trascrizionale dell'espressione dell'HLA-II	105
Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class-II molecules combined with naked DNA interleukin-12 gene transfer	104
Irradiated CIITA-positive mammary adenocarcinoma cells act as potent anti-tumor preventive vaccine by inducine tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	103
Innate and adaptive immune function of the MHC class II transactivator, CIITA, against human tumor retroviruses HTLV-2 and HTLV-1	103
La presentazione antigenica su molecole di II classe HLA è profondamente alterata in seguito a fagocitosi batterica	102
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	102
Higly stable oligomerization forms of HIV-1 Tat detected by Monoclonal antibodies and requirement of monomeric forms for the transactivating function of the HIV-1 LTR	101
The complex liaison between vulnerability to cachexia and tumor burden.	101
The molecular and cellular basis of tumor rejection after vaccination with mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	100
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator (CIITA)	100
HLA class II-dependent antigen presentation is deeply impaired in macrophage reservoir of infection	98
Imaging guided percutaneous microwave ablation of tumors.	98
Regulation of HLA antigen expression in phagocytes with mycobacteria	98
Inhibition of HTLV-2 viral replication by the MHC class II transcriptional activator (CIITA)	97
The MHC class II transactivator is a strong physiologic antagonist of HIV-1 replication	97
The replication of HTLV-2 and the expression of HLA class II transcriptional activator (CIITA) are inversely correlated	96
Regulation of HLA antigen expression in phagocytes treated with mycobacteria	96
Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis	96
Irradiated CIITA-positive mammary adenocarcinoma cells act as effective tumor cell vaccine inducing both tumor-specific CD4+ and CD8+ T immune responses and tumor rejection upon challenge.	95
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down modulation in normal human macrophages during bacterial phagocytosis.	95
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by gamma-IFN in promyelocytic cells	94
HLA-DQ expression is differently regulated from -DR and -DP	94
Induction of tumor regression by gene transfer of the MHC class II transactivator CIITA	93
Constitutive and inducible expression of HLA class II genes in normal cells is under the control of the AIR-1-encoded CIITA trans-activator	92
Metabolic Rewiring in the Tumor Microenvironment to Support Immunotherapy: A Focus on Neutrophils, Polymorphonuclear Myeloid-Derived Suppressor Cells and Natural Killer Cells	92
Expression of AIR-1/CIITA transactivator in B cell x plasmacytoma somatic cell hybrids restores HLA-DR and -DP expression, but not -DQ	91
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA	90
The AIR-1 locus-encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 productive infection by blocking the function of HIV-1 Tat	89
The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in differentiating myelomonocytic cells.	88
Tumor vaccination by CIITA-mediated MHC-II-expressing neoplastic cells	88
Strong adaptive antitumor immune response elicited by targeting tumor necrosis factor a to tumor vessels in combination with melphalan.	88
Temporal and quantitative relations between CIITA and HLA class II expression	88
The history of discovery of Interleukin-1: A fundamental cytokine of the innate immune response	87
Totale	12.188

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	57.124
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	57.124

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	1.099	0	0	0	0	0	161	44	143	264	59	138	290
2021/2022	1.101	141	133	106	111	22	19	41	95	53	128	91	161
2022/2023	1.408	151	66	123	167	97	319	0	188	173	37	51	36
2023/2024	2.818	452	438	505	488	499	220	24	25	104	17	2	44
2024/2025	1.712	13	47	320	32	84	70	79	86	221	109	133	518
2025/2026	1.902	307	235	118	553	429	260	0	0	0	0	0	0
Totale													14.125